JERUSALEM, Feb. 13,
2024 /PRNewswire/ -- Scinai Immunotherapeutics
Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on
developing inflammation and immunology (I&I) biological
products and providing CDMO services through its Scinai Bioservices
business unit, today announced the appointment of Liat Halpert as Head of Business Development
and Sales. Halpert brings extensive pharmaceutical sales and
marketing experience and joins Scinai following 14 years at
Novartis, most recently having served as Marketing and Commercial
Excellence Lead for cell and gene therapies for Central, Southern
and Eastern Europe.
Scinai's broad pharmaceutical development experience, along with
its end-to-end biologics drug development and GMP manufacturing
facility, drove the Q3 2023 launch of Scinai Bioservices, a
boutique end-to-end CDMO business unit, to assist biotech companies
efficiently bring their products to market. The company has already
signed contracts with several local biotech companies and is in
advanced discussions with a number of other potential clients.
Halpert's initial focus is to expand the business by targeting
European and US-based biotech companies to support further growth
of the CDMO business into a significant revenue generator for
Scinai as well as a key partner for small biotechnology
companies.
Scinai's R&D unit is focused on developing an innovative,
de-risked pipeline of nanosized VHH antibodies (NanoAbs) licensed
from the Max Planck Society and the University Medical Center
Göttingen in Germany. The pipeline
is targeting I&I diseases with large unmet medical needs, with
its leading product being an intradermal, local injection of a
NanoAb targeting IL-17 for the treatment of mild to moderate plaque
psoriasis. The company recently announced successful preclinical
ex-vivo trial results of its psoriasis therapy in psoriatic
human skin specimens, is currently executing an in-vivo
proof-of-concept study, and plans to enter human clinical trials in
2025. The IL-17 results follow the successful preclinical results
of Scinai's COVID-19 NanoAb therapy, which demonstrated in
pre-clinical challenge studies the potential of Scinai's NanoAbs to
prevent and treat hyper infectious viral respiratory diseases, to
be effective and safe at low doses, and to be successfully
delivered via inhalation, a uniquely convenient route of
administration. NanoAbs targeting several other I&I diseases
have also been discovered by Scinai's research partners and Scinai
has exclusive options for exclusive licenses at pre-agreed
financial terms for each of these NanoAbs. In addition to expanding
the CDMO's business development and sales activities, Halpert will
support partnering and out-licensing activities with mid and large
cap pharma companies with which Scinai plans on bringing the
NanoAbs through clinical trials and towards commercialization.
Amir Reichman, Scinai's
CEO, commented, "I am pleased to welcome Liat to Scinai. Her
pharmaceutical sales, marketing, and leadership experience, in
particular in Israel and
Europe, align with our strategic
decision to grow Scinai Bioservices CDMO into a trusted provider of
drug development services, including for preclinical and clinical
trials and GMP manufacturing for clinical supplies."
Halpert commented, "I am thrilled to join Scinai where
I'll be leading business development and sales of our
state-of-the-art end-to-end CDMO services in the global biotech
arena. I am also excited to support the partnering and
business development efforts for Scinai's NanoAb therapeutics
pipeline which in my opinion shows great potential for success. I
believe Scinai's future is promising and bright, and I look forward
to contributing and collaborating with the team."
Halpert holds an MSc. in Nutrition Science from the Hebrew University of Jerusalem.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a
biopharmaceutical company with two complementary business units,
one focused on in-house development of inflammation and immunology
(I&I) biological therapeutic products beginning with an
innovative, de-risked pipeline of nanosized VHH antibodies
(NanoAbs) targeting diseases with large unmet medical needs, and
the other a boutique CDMO providing biological drug development,
analytical methods development, clinical GMP manufacturing, and
pre-clinical and clinical trial design and execution services to
early stage biotech companies. Company website: www.scinai.com.
Company Contact
Investor Relations | +972 8 930 2529 |
ir@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, the potential of
Scinai's anti-IL-17 NanoAb, and the expansion of the
CDMO business and the timing of human clinical trials. These
forward-looking statements reflect management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of Scinai Immunotherapeutics Ltd. Risks and
uncertainties include, but are not limited to, the risk of delay
in, or Scinai's inability to conduct, its research and development
activities, including the contemplated in-vivo studies
and a clinical trial; the risk that Scinai will not remain
listed on Nasdaq; the risk that Scinai will not be successful in
expanding its CDMO business or in-license other NanoAbs; the
risk that Scinai may not be able to secure additional
capital on attractive terms, if at all; the risk that the
therapeutic and commercial potential of NanoAbs will not be met or
that Scinai will not be successful in bringing the NanoAbs towards
commercialization; the risk of a delay in the preclinical and
clinical trials data for NanoAbs, if any; the risk that our
business strategy may not be successful; the risk that the European
Investment Bank (EIB) may accelerate the financial facility under
its finance contract with Scinai; Scinai's ability to acquire
rights to additional product opportunities; Scinai's ability to
enter into collaborations on terms acceptable to Scinai or at all;
timing of receipt of regulatory approval of Scinai's manufacturing
facility in Jerusalem, if at all
or when required; the risk that the manufacturing facility will not
be able to be used for a wide variety of applications and other
vaccine and treatment technologies; and the risk that drug
development involves a lengthy and expensive process with uncertain
outcomes. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission ("SEC") on April 17, 2023, and the Company's subsequent
filings with the SEC. Scinai undertakes no obligation to revise or
update any forward-looking statement for any reason.
Logo -
https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/scinai-welcomes-liat-halpert-as-head-of-business-development-and-sales-302060602.html
SOURCE Scinai Immunotherapeutics Ltd.
